Pharmaceutical Drugs

552 Results

number of items to display at a time

Commentary

Apr 23, 2025

Strategically De-Risking U.S. Drug Supply Chains

As global trade tensions escalate, the United States may benefit from applying the concept of precision medicine to strengthen domestic resiliency in the biopharmaceutical industry. This could entail de-risking—without fully severing—drug supply chains with China.
Tool

Apr 22, 2025

Substance Use Treatment and Recovery Team Addiction Consultation Service (START ACS): An Addiction Consultation Service for Opioid Use Disorder

This guide describes the Substance Use Treatment and Recovery Team Addiction Consultation Service, a program that aims to enhance treatment initiation and ensure successful connections to follow-up care for people with opioid use disorder.
Research

Apr 14, 2025

Impact of Hospital-Physician Vertical Integration on Physician-Administered Drug Spending and Utilization

Vertical integration reduces care capacity, shifts care to hospital outpatient settings, and raises drug administration spending for hematology-oncology, ophthalmology, and rheumatology in Medicare. Drug spending also rises in hematology-oncology.
Expert Insights

Feb 26, 2025

Addressing the Opioid Crisis Among Older Americans: Strategies for Prevention, Treatment, and Supporting Families Affected by Addiction

Testimony presented before the U.S. Senate Special Committee on Aging on February 26, 2025.
Research

Feb 21, 2025

Demographic Variation In US Outpatient Hydroxychloroquine And Ivermectin Use During The COVID-19 Pandemic

Using insurance claims for 8.1 million patients from all fifty US states, we evaluated COVID-19-associated outpatient hydroxychloroquine and ivermectin use and spending throughout the public health emergency versus pre-public health emergency rates.
Research

Feb 7, 2025

A Call for Community-Shared Decisions

In light of issues such as antibiotic overuse and prescription opioid misuse, the authors present recommendations for medical decision-making that includes the community as well as the patient and clinician in order to maximize collective benefit.
Research

Feb 7, 2025

Drivers of Variation in Opioid Prescribing After Common Surgical Procedures in a Large Multihospital Healthcare System

Analysis of 25,188 surgeries at a large multihospital healthcare system clarifies sources of medically warranted and unwarranted variation in postsurgery opioid prescribing practices.
Research

Feb 7, 2025

Persistence of Social Norms Feedback on Postsurgery Opioid Prescribing Behavior: Secondary Analysis of a Randomized Clinical Trial

In a recent cluster randomized clinical trial, social norms-based feedback to surgeons significantly reduced overprescribing of postsurgery opioids. This analysis shows that the feedback's effect persisted one year after the feedback stopped.
Research

Jan 16, 2025

Examining the Impact of Eliminating the X Waiver on Buprenorphine Dispensation in 63 Counties in Pennsylvania

The study team used a quasi-experimental approach to evaluate how eliminating the X waiver affected buprenorphine prescribing in Pennsylvania.
Press

Jan 7, 2025

Typical Cost of Developing a New Drug Is Skewed by Few High-Cost Outliers

The typical cost of developing new medications may not be as high as generally believed, with a few ultra-costly medications skewing public discussions about the cost of pharmaceutical research and development, according to a new RAND study.
Research

Dec 5, 2024

Prescription Drug Prices, Rebates, and Insurance Premiums

The authors summarize evidence on drug spending, other health care costs, and premium trends in commercial markets. They also present findings from initial analyses of prescription drug data reported to the government by insurers and health plans.
Research

Nov 21, 2024

Trends in Medicare Part D Formulary Coverage for Non-insulin Diabetes Medications, 2020-2024

We assessed non-insulin diabetes drug coverage in Medicare Part D from 2020 to 2024.

Pharmaceutical Drugs

Pharmaceutical Drugs

Climate Change Affects Health and Drug Demand: Q&A with Mahshid Abir

Comparing International Prescription Drug Prices

Explore RAND’s Work on this Topic

Error

Strategically De-Risking U.S. Drug Supply Chains

Substance Use Treatment and Recovery Team Addiction Consultation Service (START ACS): An Addiction Consultation Service for Opioid Use Disorder

Impact of Hospital-Physician Vertical Integration on Physician-Administered Drug Spending and Utilization

Addressing the Opioid Crisis Among Older Americans: Strategies for Prevention, Treatment, and Supporting Families Affected by Addiction

Demographic Variation In US Outpatient Hydroxychloroquine And Ivermectin Use During The COVID-19 Pandemic

A Call for Community-Shared Decisions

Drivers of Variation in Opioid Prescribing After Common Surgical Procedures in a Large Multihospital Healthcare System

Persistence of Social Norms Feedback on Postsurgery Opioid Prescribing Behavior: Secondary Analysis of a Randomized Clinical Trial

Examining the Impact of Eliminating the X Waiver on Buprenorphine Dispensation in 63 Counties in Pennsylvania

Typical Cost of Developing a New Drug Is Skewed by Few High-Cost Outliers

Prescription Drug Prices, Rebates, and Insurance Premiums

Trends in Medicare Part D Formulary Coverage for Non-insulin Diabetes Medications, 2020-2024

Oops! An unexpected error has occurred.

RAND Headquarters

Federally Funded Research Divisions

Social and Economic Policy Divisions

International

Pharmaceutical Drugs

Pharmaceutical Drugs

Climate Change Affects Health and Drug Demand: Q&A with Mahshid Abir

Comparing International Prescription Drug Prices

Explore RAND’s Work on this Topic

Error

Strategically De-Risking U.S. Drug Supply Chains

Substance Use Treatment and Recovery Team Addiction Consultation Service (START ACS): An Addiction Consultation Service for Opioid Use Disorder

Impact of Hospital-Physician Vertical Integration on Physician-Administered Drug Spending and Utilization

Addressing the Opioid Crisis Among Older Americans: Strategies for Prevention, Treatment, and Supporting Families Affected by Addiction

Demographic Variation In US Outpatient Hydroxychloroquine And Ivermectin Use During The COVID-19 Pandemic

A Call for Community-Shared Decisions

Drivers of Variation in Opioid Prescribing After Common Surgical Procedures in a Large Multihospital Healthcare System

Persistence of Social Norms Feedback on Postsurgery Opioid Prescribing Behavior: Secondary Analysis of a Randomized Clinical Trial

Examining the Impact of Eliminating the X Waiver on Buprenorphine Dispensation in 63 Counties in Pennsylvania

Typical Cost of Developing a New Drug Is Skewed by Few High-Cost Outliers

Prescription Drug Prices, Rebates, and Insurance Premiums

Trends in Medicare Part D Formulary Coverage for Non-insulin Diabetes Medications, 2020-2024

Oops! An unexpected error has occurred.